- Home
- OCS vs CVAC Comparison
OCS vs CVAC Comparison
Compare OCS & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- CVAC
- Stock Information
- Founded
- OCS 2003
- CVAC 2000
- Country
- OCS Switzerland
- CVAC Germany
- Employees
- OCS N/A
- CVAC N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- OCS Health Care
- CVAC Health Care
- Exchange
- OCS Nasdaq
- CVAC Nasdaq
- Market Cap
- OCS 706.3M
- CVAC 637.1M
- IPO Year
- OCS N/A
- CVAC 2020
- Fundamental
- Price
- OCS $14.14
- CVAC $2.54
- Analyst Decision
- OCS Strong Buy
- CVAC Hold
- Analyst Count
- OCS 5
- CVAC 3
- Target Price
- OCS $29.20
- CVAC $10.00
- AVG Volume (30 Days)
- OCS 73.4K
- CVAC 540.3K
- Earning Date
- OCS 11-07-2024
- CVAC 11-12-2024
- Dividend Yield
- OCS N/A
- CVAC N/A
- EPS Growth
- OCS N/A
- CVAC N/A
- EPS
- OCS N/A
- CVAC N/A
- Revenue
- OCS $1,027,571.00
- CVAC $70,565,734.00
- Revenue This Year
- OCS $4.38
- CVAC $123.97
- Revenue Next Year
- OCS $905.09
- CVAC N/A
- P/E Ratio
- OCS N/A
- CVAC N/A
- Revenue Growth
- OCS N/A
- CVAC 75.11
- 52 Week Low
- OCS $9.60
- CVAC $2.22
- 52 Week High
- OCS $18.00
- CVAC $6.30
- Technical
- Relative Strength Index (RSI)
- OCS 37.01
- CVAC 34.97
- Support Level
- OCS $16.44
- CVAC $2.73
- Resistance Level
- OCS $18.00
- CVAC $2.97
- Average True Range (ATR)
- OCS 0.68
- CVAC 0.18
- MACD
- OCS -0.46
- CVAC -0.01
- Stochastic Oscillator
- OCS 3.50
- CVAC 7.55
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.